Intra-operatively customized implant coating strategies for local and controlled drug delivery to bone

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1142-1151

  Trajkovski, Branko ^a   Petersen, Ansgar ^a   Strube, Patrick ^a   Mehta, Manav ^a   Duda, Georg N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bioactive molecules; Bone morphogenetic protein; Clinical needs and challenges; Combination medical devices; Drug delivery patch; Intra operative fabrication; Medical adhesives; Scaffolds; Sleeve; Sticky strip; Stimulation of healing and regeneration

Indexed keywords

BIOACTIVE MOLECULES; BONE MORPHOGENETIC PROTEINS; CLINICAL NEEDS AND CHALLENGES; INTRA-OPERATIVE; MEDICAL ADHESIVES; MEDICAL DEVICES; SLEEVE; STICKY STRIP; STIMULATION OF HEALING AND REGENERATION;

BIOMEDICAL EQUIPMENT; COATINGS; CONTROLLED DRUG DELIVERY; SCAFFOLDS; SCAFFOLDS (BIOLOGY); TISSUE;

BONE;

ADHESIVE AGENT; ANTIBIOTIC AGENT; BIOMATERIAL; BONE CEMENT; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CALCIUM PHOSPHATE; CHONDROITIN SULFATE; COLLAGEN; COPOLYMER; CYANOACRYLATE; FIBRIN GLUE; GENTAMICIN; HYALURONIC ACID; HYDROXYAPATITE; INFUSE; LACTIC ACID 4 DIOXANONE ETHYLENE GLYCOL COPOLYMER; NANOCARRIER; OP 1; POLY(METHYL METHACRYLATE); POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYVINYL ALCOHOL; RECOMBINANT BONE MORPHOGENETIC PROTEIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT GROWTH FACTOR; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; SEALANT; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; BONE ATROPHY; BONE GRAFT; BONE INFECTION; BONE INJURY; BONE MALFORMATION; BONE MATRIX; CONTROLLED DRUG RELEASE; DEMINERALISED BONE MATRIX; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DYSPHAGIA; EDEMA; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; FRACTURE HEALING; FRACTURE NONUNION; GRAFT FAILURE; GRAFT SINTERING; HUMAN; IMPLANT; INTRAOPERATIVE PERIOD; JAW MALFORMATION; MATERIAL COATING; MEDICAL DEVICE; MICROENCAPSULATION; NANOENCAPSULATION; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOLYSIS; PRIORITY JOURNAL; RADICULITIS; REVIEW; SIDE EFFECT; TIBIA FRACTURE;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE REGENERATION; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EQUIPMENT AND SUPPLIES; EQUIPMENT DESIGN; HUMANS; INTRAOPERATIVE CARE;

EID: 84865287726     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.05.016     Document Type: Review

References (102)

1. Duda G.N., Benusch S., Haas N.P. Clinical research in partnership: musculoskeletal surgery. Chirurg 2010, 81:352-358.
2. Katz J.N. Lumbar spinal fusion. Surgical rates, costs, and complications. Spine 1995, 20:78S-83S.
3. Della Rocca G.J., Leung K.S., Pape H.C. Periprosthetic fractures: epidemiology and future projections. J. Orthop. Trauma 2011, 25(Suppl. 2):S66-S70.
4. Lad S.P., Patil C.G., Lad E.M., Boakye M. Trends in pathological vertebral fractures in the United States: 1993 to 2004. J. Neurosurg. 2007, 7:305-310.
5. Weinstein J.N., Lurie J.D., Olson P.R., Bronner K.K., Fisher E.S. United States' trends and regional variations in lumbar spine surgery: 1992-2003. Spine (Phila Pa 1976) 2006, 31:2707-2714.
6. Deyo R.A., Gray D.T., Kreuter W., Mirza S., Martin B.I. United States trends in lumbar fusion surgery for degenerative conditions. Spine (Phila Pa 1976) 2005, 30:1441-1445. (discussion 1446-1447).
7. Bergmann G., Graichen F., Rohlmann A., Bender A., Heinlein B., Duda G.N., Heller M.O., Morlock M.M. Realistic loads for testing hip implants. Biomed. Mater. Eng. 2010, 20:65-75.
8. Boden S.D., Schimandle J.H. Biologic enhancement of spinal fusion. Spine 1995, 20:113S-123S.
9. Giannoudis P.V., Einhorn T.A., Marsh D. Fracture healing: the diamond concept. Injury 2007, 38(Suppl. 4):S3-S6.
10. Sloan A., Hussain I., Maqsood M., Eremin O., El-Sheemy M. The effects of smoking on fracture healing. Surgeon 2010, 8:111-116.
11. Reid J.J., Johnson J.S., Wang J.C. Challenges to bone formation in spinal fusion. J. Biomech. 2011, 44:213-220.
12. Wessinghage D., Kisslinger E. Long-term results after cemented total hip arthroplasty in chronic polyarthritis. Orthopade 1998, 27:381-391.
13. Thillemann T.M., Pedersen A.B., Mehnert F., Johnsen S.P., Soballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone 2010, 46:946-951.
14. Pedersen A.B., Svendsson J.E., Johnsen S.P., Riis A., Overgaard S. Risk factors for revision due to infection after primary total hip arthroplasty. A population-based study of 80,756 primary procedures in the Danish Hip Arthroplasty Registry. Acta Orthop. 2010, 81:542-547.
15. Silva G.A., Coutinho O.P., Ducheyne P., Reis R.L. Materials in particulate form for tissue engineering. 2. Applications in bone. J. Tissue Eng. Regen. Med. 2007, 1:97-109.
16. Devescovi V., Leonardi E., Ciapetti G., Cenni E. Growth factors in bone repair. Chir. Organi Mov. 2008, 92:161-168.
17. Phillips A.M. Overview of the fracture healing cascade. Injury 2005, 36(Suppl. 3):S5-S7.
18. Wang C.K., Ho M.L., Wang G.J., Chang J.K., Chen C.H., Fu Y.C., Fu H.H. Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone. Biomaterials 2009, 30:4178-4186.
19. de Jonge L.T., Leeuwenburgh S.C., Wolke J.G., Jansen J.A. Organic-inorganic surface modifications for titanium implant surfaces. Pharm. Res. 2008, 25:2357-2369.
20. Macdonald M.L., Samuel R.E., Shah N.J., Padera R.F., Beben Y.M., Hammond P.T. Tissue integration of growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants. Biomaterials 2011, 32:1446-1453.
21. Strobel C., Schmidmaier G., Wildemann B. Changing the release kinetics of gentamicin from poly(D,L-lactide) implant coatings using only one polymer. Int. J. Artif. Organs 2011, 34:304-316.
22. Couto D.S., Perez-Breva L., Saraiva P., Cooney C.L. Lessons from innovation in drug-device combination products. Adv. Drug Deliv. Rev. 2012, 64:69-77.
23. Wu P., Grainger D.W. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006, 27:2450-2467.
24. Faster L.N. Faster approvals seen for drug and device combination products. BBI Newsletter 2003, 26(29):249.
25. Beth W. Medical devices and combination products. Using the Pharmaceutical Literature 2006, 233-297. Informa Healthcare.
26. Willie B.M., Petersen A., Schmidt-Bleek K., Cipitria A., Mehta M., Strube P., Lienau J., Wildemann B., Fratzl P., Duda G. Designing biomimetic scaffolds for bone regeneration: why aim for a copy of mature tissue properties if nature uses a different approach?. Soft Matter 2010, 6:4976.
27. Schmidmaier G., Herrmann S., Green J., Weber T., Scharfenberger A., Haas N.P., Wildemann B. Quantitative assessment of growth factors in reaming aspirate, iliac crest, and platelet preparation. Bone 2006, 39:1156-1163.
28. Carreon L.Y., Glassman S.D., Anekstein Y., Puno R.M. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. Spine (Phila Pa 1976) 2005, 30:E243-E246. (discussion E247).
29. Benglis D., Wang M.Y., Levi A.D. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 2008, 62:ONS423-ONS431. (discussion ONS431).
30. Garrison K.R., Shemilt I., Donell S., Ryder J.J., Mugford M., Harvey I., Song F., Alt V. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst. Rev. 2010, CD006950.
31. Argintar E., Edwards S., Delahay J. Bone morphogenetic proteins in orthopaedic trauma surgery. Injury 2011, 42:730-734.
32. Lovell T.P., Dawson E.G., Nilsson O.S., Urist M.R. Augmentation of spinal fusion with bone morphogenetic protein in dogs. Clin. Orthop. Relat. Res. 1989, 266-274.
33. Zdeblick T.A., Ghanayem A.J., Rapoff A.J., Swain C., Bassett T., Cooke M.E., Markel M. Cervical interbody fusion cages. An animal model with and without bone morphogenetic protein. Spine 1998, 23:758-765. (discussion 766).
34. Schimandle J.H., Boden S.D., Hutton W.C. Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 1995, 20:1326-1337.
35. Sandhu H.S., Kanim L.E., Toth J.M., Kabo J.M., Liu D., Delamarter R.B., Dawson E.G. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 without decortication of osseous elements. Spine 1997, 22:1171-1180.
36. Boden S.D., Martin G.J., Morone M.A., Ugbo J.L., Moskovitz P.A. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine (Phila Pa 1976) 1999, 24:1179-1185.
37. Burkus J.K., Gornet M.F., Dickman C.A., Zdeblick T.A. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J. Spinal Disord. Tech. 2002, 15:337-349.
38. Boden S.D., Kang J., Sandhu H., Heller J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002, 27:2662-2673.
39. Dimar J.R., Glassman S.D., Burkus K.J., Carreon L.Y. Clinical outcomes and fusion success at 2years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 2006, 31:2534-2539. (discussion 2540).
40. Glassman S.D., Dimar J.R., Burkus K., Hardacker J.W., Pryor P.W., Boden S.D., Carreon L.Y. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine (Phila Pa 1976) 2007, 32:1693-1698.
41. Haid R.W., Branch C.L., Alexander J.T., Burkus J.K. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004, 4:527-538. (discussion 538-529).
42. Joseph V., Rampersaud Y.R. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976) 2007, 32:2885-2890.
43. Allen R.T., Lee Y.P., Stimson E., Garfin S.R. Bone morphogenetic protein-2 (BMP-2) in the treatment of pyogenic vertebral osteomyelitis. Spine (Phila Pa 1976) 2007, 32:2996-3006.
44. Aryan H.E., Lu D.C., Acosta F.L., Ames C.P. Corpectomy followed by the placement of instrumentation with titanium cages and recombinant human bone morphogenetic protein-2 for vertebral osteomyelitis. J. Neurosurg. 2007, 6:23-30.
45. Mindea S.A., Shih P., Song J.K. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine (Phila Pa 1976) 2009, 34:1480-1484. (discussion 1485).
46. Villavicencio A.T., Burneikiene S., Nelson E.L., Bulsara K.R., Favors M., Thramann J. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J. Neurosurg. 2005, 3:436-443.
47. Burkus J.K., Sandhu H.S., Gornet M.F. Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine (Phila Pa 1976) 2006, 31:775-781.
48. Martin G.J., Boden S.D., Marone M.A., Marone M.A., Moskovitz P.A. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J. Spinal Disord. 1999, 12:179-186.
49. Buttermann G.R. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J. 2008, 8:426-435.
50. Vaidya R., Carp J., Sethi A., Bartol S., Craig J., Les C.M. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur. Spine J. 2007, 16:1257-1265.
51. Shields L.B., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., Shields C.B. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006, 31:542-547.
52. Smucker J.D., Rhee J.M., Singh K., Yoon S.T., Heller J.G. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 2006, 31:2813-2819.
53. Pradhan B.B., Bae H.W., Dawson E.G., Patel V.V., Delamarter R.B. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2006, 31:E277-E284.
54. Kanatani M., Sugimoto T., Kaji H., Kobayashi T., Nishiyama K., Fukase M., Kumegawa M., Chihara K. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J. Bone Miner. Res. 1995, 10:1681-1690.
55. Nishiyama K., Sugimoto T., Kaji H., Kanatani M., Kobayashi T., Chihara K. Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Endocrinology 1996, 137:35-41.
56. Hsu H.P., Zanella J.M., Peckham S.M., Spector M. Comparing ectopic bone growth induced by rhBMP-2 on an absorbable collagen sponge in rat and rabbit models. J. Orthop. Res. 2006, 24:1660-1669.
57. Nair L.S., Laurencin C.T. Polymers as biomaterials for tissue engineering and controlled drug delivery. Adv. Biochem. Eng. Biotechnol. 2006, 102:47-90.
58. Solchaga L.A., Hee C.K., Aguiar D.J., Ratliff J., Turner A.S., Seim H.B., Hollinger J.O., Snel L.B., Lynch S.E. Augment bone graft products compare favorably with autologous bone graft in an ovine model of lumbar interbody spine fusion. Spine 2012, 37:E461-E467.
59. Bae H.W., Zhao L., Kanim L.E., Wong P., Delamarter R.B., Dawson E.G. Intervariability and intravariability of bone morphogenetic proteins in commercially available demineralized bone matrix products. Spine (Phila Pa 1976) 2006, 31:1299-1306. (discussion 1307-1298).
60. Holt D.J., Grainger D.W. Demineralized bone matrix as a vehicle for delivering endogenous and exogenous therapeutics in bone repair. Adv. Drug Deliv. Rev. 2012, published on line (April 9, 2012). 10.1016/j.addr.2012.04.002.
61. Aebli N., Stich H., Schawalder P., Theis J.C., Krebs J. Effects of bone morphogenetic protein-2 and hyaluronic acid on the osseointegration of hydroxyapatite-coated implants: an experimental study in sheep. J. Biomed. Mater. Res. A 2005, 73:295-302.
62. Sachse A., Wagner A., Keller M., Wagner O., Wetzel W.D., Layher F., Venbrocks R.A., Hortschansky P., Pietraszczyk M., Wiederanders B., Hempel H.J., Bossert J., Horn J., Schmuck K., Mollenhauer J. Osteointegration of hydroxyapatite-titanium implants coated with nonglycosylated recombinant human bone morphogenetic protein-2 (BMP-2) in aged sheep. Bone 2005, 37:699-710.
63. Schnettler R., Knoss P.D., Heiss C., Stahl J.P., Meyer C., Kilian O., Wenisch S., Alt V. Enhancement of bone formation in hydroxyapatite implants by rhBMP-2 coating. J. Biomed. Mater. Res. B Appl. Biomater. 2009, 90:75-81.
64. Sumner D.R., Turner T.M., Urban R.M., Leven R.M., Hawkins M., Nichols E.H., McPherson J.M., Galante J.O. Locally delivered rhTGF-beta2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury. J. Orthop. Res. 2001, 19:85-94.
65. Sumner D.R., Turner T.M., Urban R.M., Turek T., Seeherman H., Wozney J.M. Locally delivered rhBMP-2 enhances bone ingrowth and gap healing in a canine model. J. Orthop. Res. 2004, 22:58-65.
66. Liu Y., de Groot K., Hunziker E.B. BMP-2 liberated from biomimetic implant coatings induces and sustains direct ossification in an ectopic rat model. Bone 2005, 36:745-757.
67. Liu Y., Enggist L., Kuffer A.F., Buser D., Hunziker E.B. The influence of BMP-2 and its mode of delivery on the osteoconductivity of implant surfaces during the early phase of osseointegration. Biomaterials 2007, 28:2677-2686.
68. Liu Y., Huse R.O., de Groot K., Buser D., Hunziker E.B. Delivery mode and efficacy of BMP-2 in association with implants. J. Dent. Res. 2007, 86:84-89.
69. Lucke M., Schmidmaier G., Sadoni S., Wildemann B., Schiller R., Haas N.P., Raschke M. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone 2003, 32:521-531.
70. Schmidmaier G., Wildemann B., Stemberger A., Haas N.P., Raschke M. Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. J. Biomed. Mater. Res. 2001, 58:449-455.
71. Schmidmaier G., Wildemann B., Cromme F., Kandziora F., Haas N.P., Raschke M. Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: a biomechanical and histological study in rats. Bone 2002, 30:816-822.
72. Wildemann B., Bamdad P., Holmer C., Haas N.P., Raschke M., Schmidmaier G. Local delivery of growth factors from coated titanium plates increases osteotomy healing in rats. Bone 2004, 34:862-868.
73. Han D., Liu W., Ao Q., Wang G. Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix. Med. Hypotheses 2008, 71:374-378.
74. Patel S., Rodriguez-Merchan E.C., Haddad F.S. The use of fibrin glue in surgery of the knee. J. Bone Joint Surg. Br. 2010, 92-B:1325-1331.
75. Shikanov A., Ezra A., Domb A.J. Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel-effect of additives. J. Control. Release 2005, 105:52-67.
76. Krasko M.Y., Golenser J., Nyska A., Nyska M., Brin Y.S., Domb A.J. Gentamicin extended release from an injectable polymeric implant. J. Control. Release 2007, 117:90-96.
77. Saito N., Murakami N., Takahashi J., Horiuchi H., Ota H., Kato H., Okada T., Nozaki K., Takaoka K. Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv. Drug Deliv. Rev. 2005, 57:1037.
78. Stadlinger B., Pilling E., Mai R., Bierbaum S., Berhardt R., Scharnweber D., Eckelt U. Effect of biological implant surface coatings on bone formation, applying collagen, proteoglycans, glycosaminoglycans and growth factors. J. Mater. Sci. Mater. Med. 2008, 19:1043-1049.
79. Chung Y.I., Ahn K.M., Jeon S.H., Lee S.Y., Lee J.H., Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J. Control. Release 2007, 121:91-99.
80. Jeon O., Kang S.W., Lim H.W., Hyung Chung J., Kim B.S. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 2006, 27:1598-1607.
81. Jeon O., Song S.J., Yang H.S., Bhang S.H., Kang S.W., Sung M.A., Lee J.H., Kim B.S. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem. Biophys. Res. Commun. 2008, 369:774-780.
82. Yilgor P., Tuzlakoglu K., Reis R.L., Hasirci N., Hasirci V. Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering. Biomaterials 2009, 30:3551-3559.
83. Kempen D.H., Lu L., Hefferan T.E., Creemers L.B., Maran A., Classic K.L., Dhert W.J., Yaszemski M.J. Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials 2008, 29:3245-3252.
84. Niu X., Feng Q., Wang M., Guo X., Zheng Q. Porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2. J. Control. Release 2009, 134:111-117.
85. Chen F.M., Zhao Y.M., Sun H.H., Jin T., Wang Q.T., Zhou W., Wu Z.F., Jin Y. Novel glycidyl methacrylated dextran (Dex-GMA)/gelatin hydrogel scaffolds containing microspheres loaded with bone morphogenetic proteins: formulation and characteristics. J. Control. Release 2007, 118:65-77.
86. Allison S.D. Analysis of initial burst in PLGA microparticles. Expert Opin. Drug Deliv. 2008, 5:615-628.
87. Xie H., Smith J.W. Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system. J. Nanobiotechnol. 2010, 8:18.
88. Bhardwaj U., Sura R., Papadimitrakopoulos F., Burgess D.J. PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. Int. J. Pharm. 2010, 384:78-86.
89. Galeska I., Kim T.K., Patil S.D., Bhardwaj U., Chatttopadhyay D., Papadimitrakopoulos F., Burgess D.J. Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels. AAPS J. 2005, 7:E231-E240.
90. Henslee A.M., Spicer P.P., Yoon D.M., Nair M.B., Meretoja V.V., Witherel K.E., Jansen J.A., Mikos A.G., Kasper F.K. Biodegradable composite scaffolds incorporating an intramedullary rod and delivering bone morphogenetic protein-2 for stabilization and bone regeneration in segmental long bone defects. Acta Biomater. 2011, 7:3627-3637.
91. M.T. Fulmer, D.A. Armbruster, R. Frigg, E.A. Gruskin, S.H. Kerr, US Patent Application 20080262630 - Drug-Impregnated Encasement (2008).
92. von Plocki S.C., Armbruster D., Klein K., Kampf K., Zlinszky K., Hilbe M., Kronen P., Gruskin E., von Rechenberg B. Biodegradable Sleeves for Metal Implants to Prevent Implant-Associated Infection: An Experimental In Vivo Study in Sheep 2012, Veterinary surgery, VS.
93. Forster H., Marotta J.S., Heseltine K., Milner R., Jani S. Bactericidal activity of antimicrobial coated polyurethane sleeves for external fixation pins. J. Orthop. Res. 2004, 22:671-677.
94. G.N. Duda, M. Manav, P. Strube, US Patent Application 20090182425 - Sheet or Tubular Structure Consisting of Elastic Biocompatible Material and its Use (2009).
95. Wang Y., Zhang L., Hu M., Wen W., Xiao H., Niu Y. Effect of chondroitin sulfate modification on rhBMP-2 release kinetics from collagen delivery system. J. Biomed. Mater. Res. A 2010, 92:693-701.
96. Mattamal G.J. U.S. FDA perspective on the regulation of cyanoacrylate polymer tissue adhesives in clinical applications. Mater. Sci. Forum 2007, 539-543:692-697.
97. Mattamal G.J. US FDA perspective on the regulations of medical-grade polymers: cyanoacrylate polymer medical device tissue adhesives. Expert Rev. Med. Devices 2008, 5:41-49.
98. Reece T.B., Maxey T.S., Kron I.L. A prospectus on tissue adhesives. Am. J. Surg. 2001, 182:40S-44S.
99. Ryou M., Thompson C.C. Tissue adhesives: a review. Tech. Gastrointest. Endosc. 2006, 8:33-37.
100. Traver M.A., Assimos D.G. New generation tissue sealants and hemostatic agents: innovative urologic applications. Rev. Urol. 2006, 8:104-111.
101. Prausnitz M.R., Langer R. Transdermal drug delivery. Nat. Biotechnol. 2008, 26:1261-1268.
102. Scheindlin S. Transdermal drug delivery: past, present, future. Mol. Interv. 2004, 4:308-312.